This is a table of type bigram and their frequencies. Use it to search & browse the list to learn more about your study carrel.
bigram | frequency |
---|---|
inflammatory bowel | 699 |
bowel disease | 629 |
clinical signs | 357 |
ibd patients | 355 |
ulcerative colitis | 256 |
mg kg | 251 |
immune response | 207 |
significantly higher | 167 |
gene expression | 157 |
healthy dogs | 143 |
immune responses | 139 |
mg dl | 135 |
flow cytometry | 132 |
present study | 132 |
class i | 129 |
increased risk | 127 |
body weight | 126 |
bone marrow | 124 |
significant difference | 124 |
weight loss | 124 |
immune system | 119 |
ng ml | 117 |
dendritic cells | 115 |
peripheral blood | 113 |
cell lines | 109 |
cd cd | 108 |
blood samples | 107 |
novel coronavirus | 105 |
cell activation | 101 |
significant differences | 100 |
statistically significant | 98 |
mg ml | 98 |
physical examination | 96 |
coronavirus disease | 95 |
heart failure | 94 |
bowel diseases | 94 |
risk factors | 93 |
cell responses | 92 |
control group | 92 |
lymph nodes | 91 |
blood pressure | 89 |
mhc class | 89 |
acute respiratory | 88 |
significantly lower | 87 |
interest reported | 86 |
median age | 84 |
may also | 83 |
nkt cells | 82 |
epithelial cells | 81 |
mitral valve | 80 |
respiratory syndrome | 80 |
systematic review | 80 |
results suggest | 79 |
liver disease | 78 |
cell surface | 78 |
diabetes mellitus | 76 |
healthy cats | 76 |
foreign bodies | 75 |
disease activity | 75 |
gastrointestinal tract | 75 |
performed using | 74 |
significantly different | 73 |
lymph node | 73 |
severe covid | 73 |
biopsy specimens | 73 |
statistical analysis | 73 |
severe acute | 72 |
colorectal cancer | 71 |
data suggest | 71 |
medical records | 70 |
doc id | 69 |
cord uid | 69 |
pg ml | 68 |
gastrointestinal disease | 68 |
mast cells | 67 |
important role | 67 |
cell lymphoma | 67 |
innate immune | 66 |
specific cd | 66 |
left ventricular | 66 |
lamina propria | 66 |
mast cell | 63 |
il ra | 63 |
small intestine | 63 |
cytokine production | 62 |
determine whether | 61 |
large bowel | 61 |
cell proliferation | 60 |
foreign body | 60 |
fecal samples | 60 |
survival time | 60 |
antigen presentation | 60 |
intestinal inflammation | 59 |
abdominal pain | 59 |
class ii | 59 |
body condition | 59 |
serum samples | 59 |
heart rate | 58 |
mrna expression | 57 |
inflammatory response | 57 |
control dogs | 57 |
mean age | 56 |
gi tract | 56 |
inkt cells | 56 |
left atrial | 56 |
chain reaction | 55 |
necrosis factor | 55 |
kidney disease | 55 |
healthy controls | 54 |
small cell | 54 |
serum cobalamin | 54 |
small bowel | 54 |
polymerase chain | 54 |
colorectal carcinoma | 53 |
clinical characteristics | 53 |
one study | 52 |
hepatic lipidosis | 52 |
side effects | 52 |
type i | 51 |
clostridium difficile | 51 |
disease severity | 51 |
western world | 51 |
inflammatory cytokines | 51 |
significantly increased | 50 |
vg vd | 50 |
cell line | 50 |
retrospective study | 50 |
gastrointestinal symptoms | 50 |
general population | 50 |
time pcr | 50 |
converting enzyme | 50 |
cd cells | 49 |
syndrome coronavirus | 49 |
heart disease | 49 |
one dog | 49 |
analyzed using | 49 |
stem cells | 49 |
deficient mice | 49 |
cell death | 49 |
congestive heart | 49 |
small intestinal | 48 |
significantly associated | 48 |
clinical practice | 48 |
viral infections | 48 |
whole blood | 48 |
previous studies | 47 |
least one | 47 |
results indicate | 47 |
valve disease | 47 |
smooth muscle | 47 |
veterinary medicine | 47 |
severe disease | 47 |
commonly used | 47 |
naturally occurring | 46 |
logistic regression | 46 |
time points | 46 |
commercially available | 46 |
cell receptor | 46 |
mononuclear cells | 46 |
clinical trials | 46 |
significant increase | 46 |
growth factor | 46 |
two groups | 46 |
immune cells | 46 |
presenting cells | 45 |
wild type | 45 |
significantly decreased | 45 |
normal dogs | 45 |
reactive protein | 45 |
cell cycle | 44 |
blood glucose | 44 |
age years | 44 |
western blot | 43 |
may contribute | 43 |
tumor necrosis | 43 |
escherichia coli | 43 |
th cells | 43 |
high levels | 43 |
animal health | 42 |
i molecules | 42 |
ahsg levels | 42 |
active disease | 42 |
health care | 42 |
higher risk | 42 |
chronic inflammatory | 42 |
oral administration | 42 |
diabetic cats | 42 |
induced colitis | 42 |
affected dogs | 41 |
disease patients | 41 |
every hours | 41 |
condition score | 40 |
significantly reduced | 40 |
collagenous colitis | 40 |
protein expression | 40 |
autoimmune diseases | 40 |
chronic kidney | 40 |
clinical trial | 40 |
cell response | 39 |
amino acid | 39 |
first time | 39 |
owned dogs | 39 |
risk factor | 39 |
serum concentrations | 39 |
united states | 39 |
measured using | 39 |
dependent manner | 39 |
pilot study | 39 |
urinary tract | 39 |
blood cell | 39 |
transcription factor | 38 |
inclusion criteria | 38 |
breed dogs | 38 |
renal disease | 38 |
cd patients | 38 |
two dogs | 38 |
reference range | 38 |
mesenchymal stem | 38 |
adaptive immune | 37 |
ex vivo | 37 |
may occur | 37 |
serum levels | 37 |
small animal | 37 |
previously described | 37 |
cell development | 37 |
prospective study | 36 |
inflammatory diseases | 36 |
case series | 36 |
adult cats | 36 |
british society | 36 |
cytokine storm | 35 |
microbiota transplantation | 35 |
statistical significance | 35 |
reactive arthritis | 35 |
adverse effects | 35 |
antigen presenting | 35 |
tumor cells | 35 |
three dogs | 35 |
clinical course | 34 |
specific antibodies | 34 |
inflammatory cells | 34 |
cell types | 34 |
mouse model | 34 |
faecal calprotectin | 33 |
years old | 33 |
high prevalence | 33 |
exocrine pancreatic | 33 |
linear foreign | 33 |
differential diagnosis | 33 |
royal canin | 33 |
respiratory disease | 33 |
teaching hospital | 33 |
plasma cells | 33 |
obese dogs | 32 |
gi disease | 32 |
world health | 32 |
serum creatinine | 32 |
chronic enteropathies | 32 |
gut microbiota | 32 |
molecular mechanisms | 32 |
ae sd | 32 |
common cause | 32 |
considered significant | 31 |
complete blood | 31 |
treg cells | 31 |
mean ae | 31 |
biopsy samples | 31 |
underlying cause | 31 |
monoclonal antibody | 31 |
lymphocytic colitis | 31 |
may play | 31 |
body fat | 31 |
red blood | 31 |
real time | 30 |
confidence interval | 30 |
innate immunity | 30 |
high level | 30 |
opportunistic infections | 30 |
acute pancreatitis | 30 |
ibd services | 30 |
fatty acids | 30 |
among patients | 30 |
signaling pathways | 30 |
hla class | 30 |
clinical presentation | 30 |
ibd patient | 30 |
dogs presented | 30 |
study aimed | 30 |
immunosuppressive therapy | 30 |
one cat | 30 |
definitive diagnosis | 29 |
social distancing | 29 |
positive correlation | 29 |
study period | 29 |
median survival | 29 |
apoptotic cells | 29 |
international organization | 29 |
previously reported | 29 |
new york | 29 |
surface expression | 29 |
health organization | 29 |
nkt cell | 29 |
dogs treated | 29 |
recent study | 29 |
adverse events | 29 |
signal transduction | 29 |
viral rna | 29 |
active ibd | 28 |
cell subsets | 28 |
monoclonal antibodies | 28 |
bartonella spp | 28 |
may cause | 28 |
biological therapy | 28 |
serum tt | 28 |
general anesthesia | 28 |
creatinine ratio | 28 |
long axis | 28 |
results show | 28 |
anal anastomosis | 28 |
ibd management | 28 |
respiratory tract | 28 |
computed tomography | 28 |
small animals | 27 |
oxidative stress | 27 |
cohort study | 27 |
healthy adult | 27 |
ml kg | 27 |
rheumatoid arthritis | 27 |
patients treated | 27 |
recent studies | 27 |
dogs received | 27 |
nervous system | 27 |
ileal pouch | 27 |
reference interval | 27 |
human medicine | 27 |
infectious agents | 27 |
acute phase | 27 |
bile acids | 27 |
expression levels | 27 |
liquid chromatography | 27 |
tritrichomonas foetus | 27 |
study showed | 27 |
results demonstrate | 27 |
two different | 26 |
dogs diagnosed | 26 |
spinal cord | 26 |
liver biopsy | 26 |
infected cells | 26 |
grade dysplasia | 26 |
hyperthyroid cats | 26 |
ace expression | 26 |
cell population | 26 |
standard deviation | 26 |
mass spectrometry | 26 |
intestinal mucosa | 26 |
right colon | 26 |
higher levels | 26 |
antigen processing | 26 |
regression analysis | 26 |
linear regression | 26 |
blood mononuclear | 26 |
normal cats | 26 |
crucial role | 26 |
exact test | 26 |
jeghers syndrome | 26 |
sessile serrated | 26 |
gi symptoms | 26 |
intensive care | 26 |
ibd units | 26 |
active colitis | 26 |
clinical features | 26 |
ibd care | 26 |
twice daily | 26 |
study population | 25 |
taken together | 25 |
histologic features | 25 |
insulin resistance | 25 |
tract infections | 25 |
underlying disease | 25 |
viral load | 25 |
repeated measures | 25 |
cardiac disease | 25 |
systolic blood | 25 |
renal function | 25 |
clinical importance | 25 |
mitral regurgitation | 25 |
clinically healthy | 25 |
cells expressing | 25 |
cell populations | 25 |
significant correlation | 25 |
natural killer | 25 |
one hundred | 25 |
also observed | 25 |
well tolerated | 25 |
several studies | 25 |
systemic lupus | 25 |
difficile infection | 25 |
time point | 25 |
anaplasma phagocytophilum | 24 |
many patients | 24 |
gastrointestinal signs | 24 |
amino acids | 24 |
data demonstrate | 24 |
beagle dogs | 24 |
human patients | 24 |
patients infected | 24 |
key role | 24 |
data indicate | 24 |
juvenile polyposis | 24 |
within days | 24 |
clinical outcome | 24 |
medical therapy | 24 |
clinical response | 24 |
serum biochemistry | 24 |
reported cases | 24 |
northern italy | 24 |
antibody titers | 24 |
urine samples | 24 |
respiratory distress | 24 |
affected cats | 24 |
cell count | 24 |
total protein | 24 |
nk cells | 24 |
survival times | 24 |
kg po | 24 |
different breeds | 24 |
proinflammatory cytokines | 24 |
public health | 24 |
case report | 24 |
viral infection | 24 |
infectious diseases | 24 |
adipose tissue | 24 |
older cats | 24 |
blood vessels | 24 |
colonic mucosa | 24 |
healthy donors | 24 |
data show | 24 |
seven dogs | 24 |
pancreatic insufficiency | 24 |
odds ratio | 24 |
disease may | 23 |
veterinary teaching | 23 |
endoscopic procedures | 23 |
faecal microbiota | 23 |
independently associated | 23 |
ganglion cells | 23 |
liver diseases | 23 |
may lead | 23 |
may result | 23 |
endothelial cells | 23 |
tlr ligands | 23 |
nine dogs | 23 |
prevalence equilibrium | 23 |
immunodeficiency virus | 23 |
lupus erythematosus | 23 |
diverticular disease | 23 |
ibd medications | 23 |
preliminary data | 23 |
cell differentiation | 23 |
dogs receiving | 23 |
infected cats | 23 |
colon cancer | 23 |
inflammatory cytokine | 23 |
cell carcinoma | 23 |
differentially expressed | 23 |
within hours | 23 |
preliminary results | 23 |
industrialized countries | 23 |
muscularis mucosae | 23 |
intestinal disease | 23 |
fold increase | 23 |
respiratory symptoms | 23 |
factors associated | 23 |
infected patients | 23 |
cardiovascular disease | 23 |
infected individuals | 23 |
blood donors | 23 |
primary ibd | 23 |
dp dt | 22 |
infected mice | 22 |
cipf whwts | 22 |
intestinal obstruction | 22 |
immune cell | 22 |
porto group | 22 |
feline infectious | 22 |
portal hypertension | 22 |
cardiac injury | 22 |
significant decrease | 22 |
small number | 22 |
cells may | 22 |
significant reduction | 22 |
left atrium | 22 |
ibd population | 22 |
intestinal tract | 22 |
juvenile polyps | 22 |
clinical disease | 22 |
tnf antagonist | 22 |
ibd database | 22 |
determined using | 22 |
inflammatory mediators | 22 |
newly industrialized | 22 |
findings suggest | 22 |
right ventricular | 22 |
clinical symptoms | 22 |
wall thickness | 22 |
many cases | 22 |
patients receiving | 22 |
widely used | 22 |
chronic pancreatitis | 22 |
blood count | 22 |
cats may | 22 |
cell tumors | 22 |
compared using | 22 |
three cats | 21 |
cobalamin concentrations | 21 |
hospitalized patients | 21 |
kg day | 21 |
control cats | 21 |
fatty acid | 21 |
crp concentrations | 21 |
stem cell | 21 |
immunohistochemical analysis | 21 |
dogs without | 21 |
tested positive | 21 |
mhc i | 21 |
telephone consultations | 21 |
cells play | 21 |
producing cells | 21 |
upper respiratory | 21 |
abdominal ultrasound | 21 |
mucosal prolapse | 21 |
gastric emptying | 21 |
critical role | 21 |
poor outcome | 21 |
patients may | 21 |
transcription factors | 21 |
systolic function | 21 |
bronchoalveolar lavage | 21 |
compounding prevalence | 21 |
pcr positive | 21 |
investigate whether | 21 |
control horses | 20 |
mg cat | 20 |
muscularis externa | 20 |
relative expression | 20 |
young dogs | 20 |
serum crp | 20 |
one third | 20 |
influenza virus | 20 |
terminal ileum | 20 |
transgenic mice | 20 |
evaluated using | 20 |
correlation coefficient | 20 |
liver function | 20 |
rpad index | 20 |
placebo group | 20 |
cytokine release | 20 |
ibd registry | 20 |
plasma concentrations | 20 |
mucosal biopsy | 20 |
current study | 20 |
plasma membrane | 20 |
target cells | 20 |
healthy control | 20 |
scoring system | 20 |
acth stimulation | 20 |
fecal microbiota | 20 |
adaptive immunity | 20 |
severe ibd | 20 |
may represent | 20 |
induced apoptosis | 20 |
united kingdom | 20 |
activity index | 20 |
therapeutic target | 20 |
two cats | 20 |
infectious peritonitis | 20 |
combination therapy | 20 |
dilated cardiomyopathy | 20 |
adult dogs | 20 |
low dose | 20 |
adhesion molecules | 20 |
may provide | 20 |
bacterial infections | 20 |
study included | 19 |
nitric oxide | 19 |
like receptor | 19 |
term follow | 19 |
six dogs | 19 |
days post | 19 |
viral replication | 19 |
antimicrobial resistance | 19 |
consecutive days | 19 |
hours post | 19 |
controlled trial | 19 |
central role | 19 |
newly diagnosed | 19 |
cell culture | 19 |
serum biochemical | 19 |
io catheter | 19 |
may help | 19 |
healthy horses | 19 |
disease process | 19 |
assessed using | 19 |
antibody responses | 19 |
human cd | 19 |
positive results | 19 |
results showed | 19 |
cats presented | 19 |
pulmonary artery | 19 |
identifi ed | 19 |
analysis showed | 19 |
three groups | 19 |
rank test | 19 |
heart murmur | 19 |
control groups | 19 |
study demonstrates | 19 |
medical treatment | 19 |
tissue samples | 19 |
stimulated cat | 19 |
plasma creatinine | 19 |
blood flow | 19 |
short axis | 19 |
healthy individuals | 19 |
like receptors | 19 |
positive cells | 19 |
infected dogs | 19 |
high risk | 19 |
total number | 19 |
increased expression | 19 |
effector cells | 18 |
th cytokines | 18 |
chronic diarrhea | 18 |
distress syndrome | 18 |
bile acid | 18 |
critically ill | 18 |
mann whitney | 18 |
intestinal microbiota | 18 |
quantitative pcr | 18 |
group compared | 18 |
coronavirus infection | 18 |
long term | 18 |
previously shown | 18 |
poor outcomes | 18 |
mean body | 18 |
cell counts | 18 |
wound healing | 18 |
focal active | 18 |
large breed | 18 |
flow cytometric | 18 |
gastrointestinal manifestations | 18 |
cells showed | 18 |
square test | 18 |
inflammatory disease | 18 |
see table | 18 |
white blood | 18 |
pv pa | 18 |
pleural effusion | 18 |
right parasternal | 18 |
protective equipment | 18 |
faecal samples | 18 |
clinical manifestations | 18 |
pulmonary fibrosis | 18 |
negative control | 18 |
colitis organisation | 18 |
cord blood | 18 |
plasma concentration | 18 |
thoracic radiographs | 18 |
primary care | 18 |
chi square | 18 |
one case | 18 |
colorectal polyps | 18 |
cd expression | 18 |
practice update | 18 |
three different | 18 |
bcs model | 18 |
gastrointestinal infection | 18 |
many cats | 18 |
middle east | 18 |
cell function | 18 |
increased serum | 17 |
samples collected | 17 |
dendritic cell | 17 |
pulmonary disease | 17 |
histologic changes | 17 |
serum concentration | 17 |
personal protective | 17 |
chronic inflammation | 17 |
bacterial overgrowth | 17 |
infectious disease | 17 |
autoimmune disease | 17 |
myxomatous mitral | 17 |
creatinine concentration | 17 |
uc patients | 17 |
inflammatory responses | 17 |
septic peritonitis | 17 |
western blotting | 17 |
healthy subjects | 17 |
supportive care | 17 |
ibd dogs | 17 |
mechanisms underlying | 17 |
study found | 17 |
type mice | 17 |
antibody levels | 17 |
animal models | 17 |
platelet aggregation | 17 |
eight dogs | 17 |
effective treatment | 17 |
clinically significant | 17 |
cell type | 17 |
catheter insertion | 17 |
ec ii | 17 |
colitis model | 17 |
five dogs | 17 |
owned cats | 17 |
oral transmission | 17 |
kg iv | 17 |
west highland | 17 |
cell membrane | 17 |
mycoplasma spp | 17 |
using flow | 17 |
esophageal sphincter | 17 |
mice treated | 17 |
east respiratory | 17 |
blood cells | 17 |
north america | 17 |
mixed breed | 17 |
gold standard | 17 |
bowel syndrome | 17 |
clinical improvement | 17 |
dogs underwent | 17 |
expression profile | 17 |
king charles | 17 |
paediatric ibd | 17 |
clinical remission | 17 |
ischemic damage | 17 |
acute severe | 17 |
reference values | 17 |
statistical analyses | 17 |
maintenance therapy | 17 |
fecal calprotectin | 17 |
highland white | 17 |
clinical history | 17 |
apoptotic cell | 17 |
central nervous | 17 |
immunological synapse | 17 |
type diabetes | 17 |
biologic therapies | 17 |
bacterial infection | 17 |
clinical data | 17 |
blot analysis | 17 |
study suggests | 17 |
respiratory rate | 17 |
clinical findings | 17 |
pulmonary edema | 17 |
university hospital | 17 |
will help | 17 |
confirmed cases | 17 |
patients affected | 17 |
affected horses | 16 |
first report | 16 |
made using | 16 |
immunosuppressive drugs | 16 |
may require | 16 |
macrophage activation | 16 |
expert commentary | 16 |
surgical intervention | 16 |
synovial fluid | 16 |
analysed using | 16 |
ibd treatment | 16 |
study evaluated | 16 |
german shepherd | 16 |
ibd disease | 16 |
colitis pattern | 16 |
specific gravity | 16 |
essential genes | 16 |
family members | 16 |
incidence range | 16 |
intracellular pathogens | 16 |
intestinal wall | 16 |
international registry | 16 |
disease course | 16 |
genomic dna | 16 |
laboratory findings | 16 |
expression profiling | 16 |
informed consent | 16 |
ibd may | 16 |
human peripheral | 16 |
five cats | 16 |
less common | 16 |
systemic corticosteroids | 16 |
specific immune | 16 |
increased significantly | 16 |
cytokine profile | 16 |
advisory board | 16 |
host immune | 16 |
pulmonary arterial | 16 |
blood gas | 16 |
pet owners | 16 |
sle patients | 16 |
epidemiological stage | 16 |
poorly understood | 16 |
also known | 16 |
fluid therapy | 16 |
treated mice | 16 |
may increase | 16 |
cavalier king | 16 |
feline pancreatic | 16 |
medical management | 16 |
examination findings | 16 |
dogs showed | 16 |
shar peis | 16 |
serum albumin | 16 |
mg day | 16 |
biologic therapy | 16 |
cobalamin supplementation | 16 |
remains unclear | 16 |
elisa kit | 16 |
bowel diarrhea | 16 |
toxoplasma gondii | 16 |
disease progression | 16 |
clinically relevant | 16 |
vgamma vdelta | 16 |
cytokine secretion | 16 |
crp concentration | 16 |
quantitative real | 16 |
tape measure | 16 |
body mass | 16 |
magnetic resonance | 16 |
different stages | 16 |
labrador retrievers | 16 |
increased levels | 16 |
bile duct | 16 |
high degree | 16 |
gut microbiome | 16 |
dogs affected | 16 |
target microorganisms | 16 |
platelet function | 16 |
dog breeds | 16 |
rectal biopsy | 16 |
confocal microscopy | 16 |
receptor antagonist | 16 |
bowel wall | 15 |
liver tissue | 15 |
cytokines il | 15 |
financial support | 15 |
time period | 15 |
analysis revealed | 15 |
strain rate | 15 |
ibd controls | 15 |
airway inflammation | 15 |
positively correlated | 15 |
increased numbers | 15 |
developing countries | 15 |
glucose concentrations | 15 |
patient management | 15 |
infection may | 15 |
companion animals | 15 |
solitary rectal | 15 |
iris stage | 15 |
connective tissue | 15 |
may reflect | 15 |
corticosteroid treatment | 15 |
cells express | 15 |
ischemic bowel | 15 |
invasive carcinoma | 15 |
clinical evidence | 15 |
i antigen | 15 |
liver enzymes | 15 |
treatment groups | 15 |
experimental colitis | 15 |
patients without | 15 |
cobalamin concentration | 15 |
also occur | 15 |
hyperplastic polyps | 15 |
two cases | 15 |
mild disease | 15 |
cellular immune | 15 |
binding site | 15 |
high serum | 15 |
protease inhibitor | 15 |
clinical parameters | 15 |
echocardiographic parameters | 15 |
cats received | 15 |
electron microscopy | 15 |
showed significant | 15 |
ko mice | 15 |
future studies | 15 |
inflammatory drugs | 15 |
upper limit | 15 |
disease control | 15 |
survival rate | 15 |
canine ibd | 15 |
pancreatic lipase | 15 |
surgical resection | 15 |
animal hospital | 15 |
polyposis syndrome | 15 |
small molecules | 15 |
antibody response | 15 |
serum ccl | 15 |
remains unknown | 15 |
information regarding | 15 |
mouse models | 15 |
digestive diseases | 15 |
dis doi | 15 |
humoral immune | 15 |
signaling pathway | 15 |
corticosteroid use | 15 |
systemic inflammatory | 15 |
less likely | 15 |
chronic intestinal | 15 |
ulcer syndrome | 15 |
predictive value | 15 |
protective immunity | 15 |
calculated using | 15 |
six healthy | 15 |
surgical treatment | 15 |
commonly reported | 15 |
treatment group | 15 |
ethics committee | 15 |
intestinal epithelium | 15 |
ibd nurses | 15 |
european society | 15 |
mucosal inflammation | 15 |
corticosteroid therapy | 15 |
previous study | 15 |
invasive adenocarcinoma | 15 |
primary human | 15 |
dna vaccine | 15 |
baseline cortisol | 15 |
lower esophageal | 15 |
significant association | 15 |
veterinary hospital | 14 |
higher concentrations | 14 |
right ventricle | 14 |
first line | 14 |
soluble factors | 14 |
therapeutic targets | 14 |
neurological signs | 14 |
steroid use | 14 |
specific antibody | 14 |
significantly correlated | 14 |
one week | 14 |
within minutes | 14 |
rectal ulcer | 14 |
study suggest | 14 |
cov infection | 14 |
expression profiles | 14 |
infectious colitis | 14 |
pcr testing | 14 |
cytokine expression | 14 |
drug administration | 14 |
small breed | 14 |
bl mice | 14 |
mice lacking | 14 |
cell epitopes | 14 |
helicobacter spp | 14 |
tmprss expression | 14 |
rapid spread | 14 |
groups using | 14 |
ct scan | 14 |
ventricular hypertrophy | 14 |
immunosorbent assay | 14 |
left ventricle | 14 |
urea nitrogen | 14 |
companion animal | 14 |
aspiration pneumonia | 14 |
three patients | 14 |
clinically ill | 14 |
interquartile range | 14 |
antibiotic treatment | 14 |
feline liver | 14 |
ccl concentrations | 14 |
mycobacterium tuberculosis | 14 |
disease network | 14 |
lung injury | 14 |
myeloid cells | 14 |
nod mice | 14 |
igg antibodies | 14 |
severe cases | 14 |
whenever possible | 14 |
canine patients | 14 |
single cell | 14 |
arterial blood | 14 |
lgl lymphoma | 14 |
diagnostic tests | 14 |
cats without | 14 |
currently available | 14 |
antibiotic therapy | 14 |
lymphocyte count | 14 |
novel protein | 14 |
free wall | 14 |
way anova | 14 |
mice showed | 14 |
prognostic value | 14 |
mechanisms involved | 14 |
commonly associated | 14 |
previous bp | 14 |
apc gene | 14 |
tnf antagonists | 14 |
mucosal architecture | 14 |
final diagnosis | 14 |
may affect | 14 |
canine inflammatory | 14 |
randomized controlled | 14 |
lavage fluid | 14 |
hypertrophic cardiomyopathy | 14 |
cats treated | 14 |
internal medicine | 14 |
ibd cases | 14 |
gastrointestinal endoscopy | 14 |
laboratory data | 14 |
type ii | 14 |
microbe interactions | 14 |
cells also | 14 |
apparently healthy | 14 |
adoptive transfer | 14 |
largely unknown | 14 |
golden retriever | 14 |
idiopathic pulmonary | 14 |
viral entry | 14 |
may suggest | 14 |
domestic shorthair | 14 |
kit vegf | 14 |
tumor cell | 14 |
situ hybridization | 14 |
even though | 14 |
beneficial effect | 14 |
lactococcus lactis | 14 |
active metabolite | 14 |
chronic diseases | 14 |
animal model | 14 |
sinus rhythm | 14 |
pancreatic disease | 14 |
reverse transcription | 14 |
older dogs | 14 |
helicobacter pylori | 14 |
overall survival | 14 |
lung disease | 14 |
also found | 14 |
dna aneuploidy | 14 |
large intestine | 14 |
female dogs | 14 |
diagnostic value | 14 |
common clinical | 14 |
abdominal cavity | 14 |
campylobacter jejuni | 14 |
pressure measurement | 14 |
published data | 14 |
mesenteric lymph | 14 |
pulmonary hypertension | 14 |
tract disease | 14 |
cardiac diseases | 14 |
effector functions | 14 |
cats compared | 13 |
research exclusion | 13 |
protein concentration | 13 |
new therapeutic | 13 |
salmonella sp | 13 |
lateral recumbency | 13 |
first step | 13 |
oral cobalamin | 13 |
different types | 13 |
acvim class | 13 |
gastroenterology guidance | 13 |
total thyroxine | 13 |
rare event | 13 |
study group | 13 |
previously demonstrated | 13 |
highly expressed | 13 |
distemper virus | 13 |
biochemistry profile | 13 |
bayesian inverse | 13 |
ibd izaa | 13 |
fractional shortening | 13 |
observational study | 13 |
clinical examination | 13 |
host cell | 13 |
among ibd | 13 |
using high | 13 |
major role | 13 |
cd foxp | 13 |
cats diagnosed | 13 |
pulmonic stenosis | 13 |
multivariate analysis | 13 |
surface area | 13 |
matched control | 13 |
new insights | 13 |
control study | 13 |
one patient | 13 |
proteins involved | 13 |
dogs using | 13 |
spec cpl | 13 |
first study | 13 |
also performed | 13 |
skeletal muscle | 13 |
cell tolerance | 13 |
study provides | 13 |
care unit | 13 |
gel electrophoresis | 13 |
mitral valves | 13 |
giardia infection | 13 |
chronic disease | 13 |
biopsy specimen | 13 |
lung tissue | 13 |
mhc ii | 13 |
viral shedding | 13 |
cytokine il | 13 |
crohn disease | 13 |
early stage | 13 |
labrador retriever | 13 |
tumor development | 13 |
immunized mice | 13 |
aga clinical | 13 |
gastroesophageal reflux | 13 |
tlr stimulation | 13 |
previously validated | 13 |
actin cytoskeleton | 13 |
wilcoxon signed | 13 |
linked immunosorbent | 13 |
elevated levels | 13 |
virus infection | 13 |
reference ranges | 13 |
two patients | 13 |
underlying causes | 13 |
shortening fraction | 13 |
normally distributed | 13 |
beta i | 13 |
mortality rate | 13 |
median time | 13 |
cardiac troponin | 13 |
fatality rate | 13 |
care providers | 13 |
serrated polyps | 13 |
soft tissue | 13 |
surface molecules | 13 |
emergency department | 13 |
differential expression | 13 |
rv function | 13 |
urine ph | 13 |
mrna levels | 13 |
cranial fossa | 13 |
right lateral | 13 |
surface markers | 13 |
digestive system | 13 |
clinical score | 13 |
gene mutations | 13 |
cells stimulated | 13 |
chronic colitis | 13 |
troponin i | 13 |
serum piiinp | 13 |
assess whether | 13 |
inhibitory effect | 13 |
surgical correction | 13 |
tricuspid valve | 13 |
ibd flare | 13 |
better understanding | 13 |
serum total | 13 |
human gut | 13 |
intramucosal adenocarcinoma | 13 |
control mice | 13 |
ibd study | 13 |
case reports | 13 |
human monocytes | 13 |
urine specific | 13 |
disease flare | 13 |
cats receiving | 13 |
confirmed covid | 13 |
study shows | 13 |
mice compared | 13 |
rrna gene | 13 |
serum ht | 13 |
cobalamin deficiency | 13 |
normal horses | 13 |
watery diarrhea | 13 |
mechanical ventilation | 13 |
geriatric cats | 13 |
bacterial culture | 13 |
tt concentrations | 13 |
four dogs | 13 |
body temperature | 13 |
extracellular matrix | 13 |
obtained using | 13 |
measures anova | 13 |
acute onset | 13 |
adenomatous polyposis | 13 |
caudal cranial | 13 |
elevated liver | 13 |
derived mesenchymal | 13 |
giardia spp | 13 |
review article | 13 |
young cats | 12 |
cytokine profiles | 12 |
facs analysis | 12 |
weight gain | 12 |
needle aspiration | 12 |
positive control | 12 |
serrated polyp | 12 |
ventricular septal | 12 |
disease processes | 12 |
also showed | 12 |
year old | 12 |
epithelial cell | 12 |
ibd unit | 12 |
continuous variables | 12 |
will require | 12 |
congenital heart | 12 |
chronic gastrointestinal | 12 |
canine adipose | 12 |
nonsteroidal anti | 12 |
patient care | 12 |
prevent infection | 12 |
inactive disease | 12 |
renal failure | 12 |
large cohort | 12 |
human ibd | 12 |
regulatory cells | 12 |
stage iii | 12 |
using elisa | 12 |
severe clinical | 12 |
clinical diagnosis | 12 |
marrow derived | 12 |
cancer cell | 12 |
surveillance epidemiology | 12 |
existing digestive | 12 |
large number | 12 |
arachidonic acid | 12 |
aortic stenosis | 12 |
immune suppression | 12 |
inhibitory effects | 12 |
group dogs | 12 |
listeria monocytogenes | 12 |
promoter activity | 12 |
task force | 12 |
related complications | 12 |
multiple sclerosis | 12 |
diagnostic imaging | 12 |
sick cats | 12 |
alt levels | 12 |
using spss | 12 |
potential therapeutic | 12 |
study using | 12 |
surgical masks | 12 |
median follow | 12 |
mmol mol | 12 |
systemic inflammation | 12 |
feline coronavirus | 12 |
airway obstruction | 12 |
novel therapeutic | 12 |
biological activity | 12 |
significant changes | 12 |
antigenic peptides | 12 |
tg therapy | 12 |
endoscopic biopsies | 12 |
respiratory infections | 12 |
annular hypoplasia | 12 |
immune regulation | 12 |
vascular endothelial | 12 |
recently described | 12 |
new coronavirus | 12 |
hemorrhagic colitis | 12 |
clinical outcomes | 12 |
cancer cells | 12 |
feline immunodeficiency | 12 |
vice versa | 12 |
per day | 12 |
tlr ligand | 12 |
cytokine response | 12 |
white terriers | 12 |
heart size | 12 |
alanine aminotransferase | 12 |
urgent consultations | 12 |
angiotensin system | 12 |
previous work | 12 |
gall bladder | 12 |
cerebrospinal fluid | 12 |
two distinct | 12 |
intraepithelial lymphocytes | 12 |
intestinal epithelial | 12 |
cryptosporidium spp | 12 |
endoplasmic reticulum | 12 |
changes associated | 12 |
cardiac function | 12 |
human immunodeficiency | 12 |
single nucleotide | 12 |
bacterial groups | 12 |
nucleotide polymorphisms | 12 |
neutralizing antibodies | 12 |
inflammatory effects | 12 |
cd vegf | 12 |
colonic epithelial | 12 |
heat shock | 12 |
present data | 12 |
large numbers | 12 |
well known | 12 |
dynamical system | 12 |
significantly greater | 12 |
clinical suspicion | 12 |
canned food | 12 |
still alive | 12 |
included dogs | 12 |
fine needle | 12 |
evidence suggests | 12 |
respiratory signs | 12 |
acth cortisol | 12 |
limited colitis | 12 |
endoscopy room | 12 |
clostridium perfringens | 12 |
high rate | 12 |
lower levels | 12 |
wide range | 12 |
nmoles min | 12 |
clinical relevance | 12 |
min mg | 12 |
intestinal small | 12 |
acute self | 12 |
test food | 12 |
year period | 12 |
jak inhibitors | 12 |
colonic mucosal | 12 |
immunosuppressed patients | 12 |
tumor growth | 12 |
decreased significantly | 12 |
response rate | 12 |
increasing age | 12 |
degenerative mitral | 12 |
boehringer ingelheim | 12 |
ibd flares | 12 |
tissue doppler | 12 |
losing enteropathy | 12 |
genetic testing | 12 |
system may | 12 |
may indicate | 12 |
stage ii | 12 |
hyperplastic polyp | 12 |
protective effect | 12 |
significant effect | 12 |
epidemiological stages | 12 |
identified using | 12 |
omeprazole treatment | 12 |
day pi | 12 |
relatively low | 12 |
one group | 12 |
mitotic figures | 12 |
may influence | 12 |
plasma phosphate | 12 |
pi concentrations | 12 |
close contact | 12 |
based study | 12 |
edta blood | 12 |
clinical activity | 12 |
polyarteritis nodosa | 12 |
mediated diseases | 12 |
nasal discharge | 12 |
various breeds | 12 |
greater risk | 12 |
recommendations regarding | 12 |
fat percentage | 12 |
often used | 12 |
procoagulant activity | 12 |
arterial hypertension | 12 |
liver biopsies | 12 |
maine coon | 12 |
nutritional support | 12 |
plasma samples | 12 |
ileal biopsies | 12 |
also seen | 12 |
diagnostic tool | 12 |
breast milk | 12 |
filtration rate | 12 |
acute colitis | 11 |
phagocytic activity | 11 |
severe ulcerative | 11 |
platelet count | 11 |
disease status | 11 |
pattern recognition | 11 |
canine cp | 11 |
indeterminate colitis | 11 |
incidence rate | 11 |
cats will | 11 |
thymic epithelial | 11 |
surface epithelium | 11 |
domestic short | 11 |
colitis cystica | 11 |
commonly seen | 11 |
ibd therapies | 11 |
groups based | 11 |
confidence intervals | 11 |
hepatic disease | 11 |
histologic pattern | 11 |
spinal canal | 11 |
randomised controlled | 11 |
pressure liquid | 11 |
laboratory abnormalities | 11 |
probnp concentration | 11 |
dextran sulfate | 11 |
also increased | 11 |
positively associated | 11 |
idexx laboratories | 11 |
state university | 11 |
worse prognosis | 11 |
staphylococcus aureus | 11 |
healthcare professionals | 11 |
dietary management | 11 |
derived macrophages | 11 |
patients undergoing | 11 |
weight management | 11 |
pivotal role | 11 |
resonance imaging | 11 |
rectal temperature | 11 |
sample collection | 11 |
feline population | 11 |
dogs compared | 11 |
cardiac size | 11 |
mixed model | 11 |
total bacteria | 11 |
primary vaccination | 11 |
alveolar macrophages | 11 |
multiple comparisons | 11 |
analysis using | 11 |
kg orally | 11 |
intracellular cytokine | 11 |
extraintestinal manifestations | 11 |
rising incidence | 11 |
dogs fed | 11 |
chain fatty | 11 |
helicobacter infection | 11 |
latin america | 11 |
derived dendritic | 11 |
mm hg | 11 |
factor receptor | 11 |
mucosal bacteria | 11 |
results obtained | 11 |
patients reported | 11 |
drugs used | 11 |
rectal bleeding | 11 |
positive dogs | 11 |
immunosuppressive agents | 11 |
histologically confirmed | 11 |
tyrosine kinase | 11 |
adult horses | 11 |
lower urinary | 11 |
interview covid | 11 |
urine protein | 11 |
axis view | 11 |
normal controls | 11 |
grade iii | 11 |
colitis foundation | 11 |
treated group | 11 |
pda occlusion | 11 |
serine protease | 11 |
protective measures | 11 |
autosomal recessive | 11 |
regression models | 11 |
ten dogs | 11 |
mononuclear cell | 11 |
immunocompromised patients | 11 |
mediated immunity | 11 |
cell numbers | 11 |
stimulation test | 11 |
healthy beagle | 11 |
sick dogs | 11 |
received financial | 11 |
clinically normal | 11 |
see chapter | 11 |
care must | 11 |
goblet cells | 11 |
transit time | 11 |
increased frequency | 11 |
high pressure | 11 |
patients suffering | 11 |
nutritional status | 11 |
response syndrome | 11 |
colorectal biopsy | 11 |
transthoracic echocardiography | 11 |
higher prevalence | 11 |
protein kinase | 11 |
cats presenting | 11 |
albumin concentration | 11 |
vascular lesions | 11 |
international meeting | 11 |
activation markers | 11 |
clinical cases | 11 |
per year | 11 |
canine lymphoma | 11 |
cfu ml | 11 |
tumor suppressor | 11 |
asymptomatic patients | 11 |
endoscopic polypectomy | 11 |
gastroenterol doi | 11 |
differ significantly | 11 |
may predispose | 11 |
doppler echocardiography | 11 |
room temperature | 11 |
foxp treg | 11 |
test results | 11 |
highly conserved | 11 |
least two | 11 |
image quality | 11 |
previously presented | 11 |
tissue cysts | 11 |
care workers | 11 |
samples obtained | 11 |
prognostic factors | 11 |
cell lysates | 11 |
tumour cell | 11 |
point scale | 11 |
positive test | 11 |
histopathologic examination | 11 |
active ulcerative | 11 |
sinonasal aspergillosis | 11 |
sectional study | 11 |
higher serum | 11 |
cystica profunda | 11 |
age groups | 11 |
blood sampling | 11 |
doppler imaging | 11 |
times higher | 11 |
bowel dis | 11 |
effusion samples | 11 |
required hospitalization | 11 |
also evaluated | 11 |
first case | 11 |
candidate genes | 11 |
possible role | 11 |
gastrointestinal diseases | 11 |
supplementary table | 11 |
coronavirus sars | 11 |
affected patients | 11 |
also significantly | 11 |
diagnostic accuracy | 11 |
venous blood | 11 |
valve repair | 11 |
performance liquid | 11 |
normal serum | 11 |
inflamm bowel | 11 |
cmv infection | 11 |
immunosuppressive medications | 11 |
patients compared | 11 |
metabolic network | 11 |
clostridioides difficile | 11 |
alkaline phosphatase | 11 |
canine distemper | 11 |
cutoff value | 11 |
following treatment | 11 |
ifng production | 11 |
may serve | 11 |
sigmoid colon | 11 |
fecal ccp | 11 |
atrial fibrillation | 11 |
bordetella bronchiseptica | 11 |
per cent | 11 |
faecalibacterium spp | 11 |
adverse reactions | 11 |
biologically active | 11 |
global pandemic | 11 |
retrospectively reviewed | 11 |
findings indicate | 11 |
tmprss mrna | 11 |
signed rank | 11 |
transit times | 11 |
biochemical analysis | 11 |
statistical difference | 11 |
chronic gi | 11 |
obese cats | 11 |
hematopoietic stem | 11 |
lg kg | 11 |
might play | 11 |
positive samples | 11 |
lipase immunoreactivity | 11 |
significant higher | 11 |
vitro studies | 11 |
gastric acid | 11 |
intestinal mucosal | 11 |
aortic root | 11 |
acute inflammation | 11 |
sulfate sodium | 11 |
transforming growth | 11 |
peak velocity | 11 |
ibd evolution | 11 |
high affinity | 11 |
clinical priorities | 11 |
limited data | 11 |
infected pneumonia | 11 |
cell compartment | 11 |
least weeks | 11 |
ejection fraction | 11 |
poor prognosis | 11 |
portal vein | 11 |
days later | 11 |
elective surgery | 11 |
specific primers | 11 |
izaa sha | 11 |
regulatory role | 11 |
familial adenomatous | 11 |
cd positive | 11 |
case fatality | 11 |
randomly assigned | 11 |
vaccinia virus | 11 |
drug interactions | 11 |
success rate | 11 |
american college | 11 |
high doses | 11 |
prospective studies | 11 |
interstitial lung | 10 |
tcc cell | 10 |
angiotensin ii | 10 |
dose reduction | 10 |
idiopathic inflammatory | 10 |
another study | 10 |
lipid rafts | 10 |
expressing cd | 10 |
disease date | 10 |
routine laboratory | 10 |
descriptive study | 10 |
recent evidence | 10 |
data analysis | 10 |
influenza vaccine | 10 |
wall thickening | 10 |
current coronavirus | 10 |
yersinia enterocolitica | 10 |
cell tumours | 10 |
disease behavior | 10 |
disease susceptibility | 10 |
inflammatory properties | 10 |
will need | 10 |
quantitative rt | 10 |
atopic dermatitis | 10 |
cellular immunity | 10 |
limited information | 10 |
clinical setting | 10 |
term outcome | 10 |
knockout mice | 10 |
positive cats | 10 |
drinking water | 10 |
saccharomyces cerevisiae | 10 |
see later | 10 |
gut microbial | 10 |
mucosal immune | 10 |
rank sum | 10 |
within weeks | 10 |
sars coronavirus | 10 |
ss patients | 10 |
cytometry analysis | 10 |
treatment period | 10 |
expression analysis | 10 |
microsatellite instability | 10 |
paediatric inflammatory | 10 |
correlation coefficients | 10 |
antigen specific | 10 |
canonical wnt | 10 |
studies show | 10 |
serious viral | 10 |
treated dogs | 10 |
ctl response | 10 |
insertion time | 10 |
serum citrulline | 10 |
important part | 10 |
dogs may | 10 |
early stages | 10 |
inkt cell | 10 |
serum cortisol | 10 |
type iv | 10 |
four different | 10 |
ht concentrations | 10 |
study demonstrated | 10 |
normal reference | 10 |
nodular regenerative | 10 |
diagnostic utility | 10 |
findings included | 10 |
cell entry | 10 |
soluble form | 10 |
canine tcc | 10 |
regenerative hyperplasia | 10 |
pcr test | 10 |
serum bile | 10 |
additional studies | 10 |
serrated adenomas | 10 |
dominant negative | 10 |
studies will | 10 |
different time | 10 |
laboratory tests | 10 |
ibd co | 10 |
health status | 10 |
increased incidence | 10 |
mice deficient | 10 |
veterinary practice | 10 |
phase ii | 10 |
naturally infected | 10 |
salmonella typhimurium | 10 |
immune mediated | 10 |
endothelial growth | 10 |
younger cats | 10 |
calcium influx | 10 |
glycaemic control | 10 |
bifidobacterium spp | 10 |
kg bid | 10 |
gene mutation | 10 |
pandemic era | 10 |
taiwan university | 10 |
recognition receptors | 10 |
regional lymph | 10 |
herpes virus | 10 |
signalling pathways | 10 |
disease management | 10 |
lymphoid aggregates | 10 |
protective immune | 10 |
adoptively transferred | 10 |
cell growth | 10 |
related genes | 10 |
electrolyte abnormalities | 10 |
serum ca | 10 |
elimination half | 10 |
genes involved | 10 |
glucose tolerance | 10 |
peripheral tolerance | 10 |
diarrhea may | 10 |
two types | 10 |
nucleic acid | 10 |
national taiwan | 10 |
ecco taskforce | 10 |
endemic area | 10 |
inflammatory immune | 10 |
airway disease | 10 |
autosomal dominant | 10 |
negative selection | 10 |
low prevalence | 10 |
excluded due | 10 |
educational material | 10 |
differed significantly | 10 |
plasma levels | 10 |
congenital cardiac | 10 |
high incidence | 10 |
cd tc | 10 |
signs included | 10 |
every weeks | 10 |
paneth cell | 10 |
evaluate whether | 10 |
progenitor cells | 10 |
tlr gene | 10 |
peptide loading | 10 |
information found | 10 |
host cells | 10 |
also possible | 10 |
glucose concentration | 10 |
many countries | 10 |
recent years | 10 |
phase i | 10 |
intestinal bacterial | 10 |
lower airway | 10 |
ioibd update | 10 |
plasma fgf | 10 |
inflammatory conditions | 10 |
descriptive statistics | 10 |
concurrent diseases | 10 |
causative agent | 10 |
active infection | 10 |
clotrimazole cream | 10 |
ctl responses | 10 |
decreased serum | 10 |
right pulmonary | 10 |
murine models | 10 |
grade i | 10 |
strongly associated | 10 |
receiver operating | 10 |
crp levels | 10 |
commonly isolated | 10 |
tt concentration | 10 |
ace mrna | 10 |
clinical studies | 10 |
feline gastrointestinal | 10 |
wallis test | 10 |
male dogs | 10 |
septic foals | 10 |
cytokine levels | 10 |
platelet counts | 10 |
inverse problems | 10 |
septic shock | 10 |
chronic gastritis | 10 |
phase protein | 10 |
five patients | 10 |
negative results | 10 |
hong kong | 10 |
ml min | 10 |
coalescing incidence | 10 |
prevalence doubling | 10 |
pcr assay | 10 |
related diseases | 10 |
severe uc | 10 |
present work | 10 |
fecal iga | 10 |
results may | 10 |
elevated serum | 10 |
canine parvovirus | 10 |
coronavirus pandemic | 10 |
rescue therapy | 10 |
blood lymphocytes | 10 |
lg ml | 10 |
coronavirus pneumonia | 10 |
molecular events | 10 |
seasonal influenza | 10 |
several days | 10 |
total rna | 10 |
cats suffering | 10 |
month period | 10 |
remained unchanged | 10 |
reference intervals | 10 |
asa sulfasalazine | 10 |
needle biopsy | 10 |
expression level | 10 |
lad lab | 10 |
dynamical systems | 10 |
cell lineage | 10 |
lesser extent | 10 |
may contain | 10 |
intracellular bacteria | 10 |
probnp concentrations | 10 |
disease caused | 10 |
cell contact | 10 |
peptide binding | 10 |
consultation room | 10 |
endemic areas | 10 |
gastrointestinal disorders | 10 |
patients will | 10 |
selective autophagy | 10 |
least days | 10 |
identify patients | 10 |
stress response | 10 |
nuclear translocation | 10 |
data obtained | 10 |
therapeutic potential | 10 |
cell survival | 10 |
significant change | 10 |
ao ratio | 10 |
epub ahead | 10 |
receptor expression | 10 |
chf cats | 10 |
glomerular filtration | 10 |
including inflammatory | 10 |
like immunoreactivity | 10 |
lymphoid organs | 10 |
viral clearance | 10 |
diet change | 10 |
lower compared | 10 |
angiotensin converting | 10 |
digestive symptoms | 10 |
potential risk | 10 |
prospectively enrolled | 10 |
wide association | 10 |
peritoneal macrophages | 10 |
giardia duodenalis | 10 |
giant cell | 10 |
study design | 10 |
may induce | 10 |
inflammatory changes | 10 |
using non | 10 |
inflammatory liver | 10 |
treatment strategies | 10 |
provide evidence | 10 |
adaptor proteins | 10 |
high cd | 10 |
anal sac | 10 |
ibd porto | 10 |
proton pump | 10 |
medical center | 10 |
esophageal disease | 10 |
dss colitis | 10 |
different groups | 10 |
six months | 10 |
shepherd dogs | 10 |
gd cells | 10 |
studies evaluating | 10 |
cats undergoing | 10 |
mg twice | 10 |
clinical use | 10 |
ibs patients | 10 |
ascitic fluid | 10 |
immune complexes | 10 |
antimicrobial susceptibility | 9 |
serum igf | 9 |
oxygen species | 9 |
lps stimulation | 9 |
diseases associated | 9 |
health emergency | 9 |
teg parameters | 9 |
patient population | 9 |
molecular biology | 9 |
antigen test | 9 |
increased compared | 9 |
cells expressed | 9 |
histological examination | 9 |
also reported | 9 |
drug targets | 9 |
positive predictive | 9 |
type immune | 9 |
molecular mimicry | 9 |
diseased dogs | 9 |
clinical conditions | 9 |
protein production | 9 |
orally administered | 9 |
using commercial | 9 |
fish analysis | 9 |
wt mice | 9 |
common causes | 9 |
compared among | 9 |
disease care | 9 |
intervertebral disc | 9 |
essential host | 9 |
bowel ultrasonography | 9 |
culture supernatants | 9 |
cell subset | 9 |
important implications | 9 |
western blots | 9 |
results suggested | 9 |
serum alp | 9 |
stool samples | 9 |
cd ab | 9 |
fold change | 9 |
expression pattern | 9 |
cell number | 9 |
compatible clinical | 9 |
motility disorders | 9 |
celiac sprue | 9 |
time intervals | 9 |
induced production | 9 |
dose dependent | 9 |
corona virus | 9 |
operating characteristic | 9 |
essential role | 9 |
therapeutic option | 9 |
staphylococcus spp | 9 |
human host | 9 |
serrated adenoma | 9 |
cells derived | 9 |
cardiac biomarkers | 9 |
remained significant | 9 |
cell lymphomas | 9 |
pediatric ibd | 9 |
clinical study | 9 |
campylobacter spp | 9 |
retrospective analysis | 9 |
shorthair cats | 9 |
remaining cats | 9 |
among children | 9 |
constitutively expressed | 9 |
gi diseases | 9 |
using quantitative | 9 |
cardiac murmur | 9 |
orally every | 9 |
epidemiological studies | 9 |
fusion protein | 9 |
basement membrane | 9 |
mucous membranes | 9 |
average age | 9 |
studies showed | 9 |
give rise | 9 |
anti tnf | 9 |
unclear whether | 9 |
social media | 9 |
using specific | 9 |
veress needle | 9 |
vascular ectasia | 9 |
high performance | 9 |
cardiac output | 9 |
specific treatment | 9 |
south korea | 9 |
associated risk | 9 |
medical university | 9 |
human cells | 9 |
patient cohorts | 9 |
sternal recumbency | 9 |
cross presentation | 9 |
bcs diagnosis | 9 |
older individuals | 9 |
marginal zone | 9 |
lower respiratory | 9 |
quality care | 9 |
icu patients | 9 |
protein levels | 9 |
assay variability | 9 |
disease cats | 9 |
contrast radiography | 9 |
breast cancer | 9 |
symptomatic patients | 9 |
often present | 9 |
insurance company | 9 |
old man | 9 |
genes encoding | 9 |
phase proteins | 9 |
germinal center | 9 |
chronic enteropathy | 9 |
adaptor protein | 9 |
cell activity | 9 |
immune status | 9 |
tgn levels | 9 |
liver injury | 9 |
mediated immune | 9 |
viral particles | 9 |
also determined | 9 |
specific anti | 9 |
allergic asthma | 9 |
biochemical profile | 9 |
high resolution | 9 |
suppressor gene | 9 |
disease onset | 9 |
outpatient visits | 9 |
granulomatous inflammation | 9 |
concerns regarding | 9 |
investigated whether | 9 |
stochastic process | 9 |
longer duration | 9 |
using different | 9 |
single dose | 9 |
tc cells | 9 |
lymphocytic infiltration | 9 |
older age | 9 |
duodenal biopsies | 9 |
emergency room | 9 |
neuronal dysplasia | 9 |
mean hr | 9 |
immune escape | 9 |
ibd covid | 9 |
clinical sign | 9 |
cortisol concentration | 9 |
clinical significance | 9 |
classification system | 9 |
ii molecules | 9 |
second stage | 9 |
mean values | 9 |
prothrombin time | 9 |
viral loads | 9 |
tumour necrosis | 9 |
least months | 9 |
pseudomembranous colitis | 9 |
cells within | 9 |
also measured | 9 |
cases may | 9 |
irritable bowel | 9 |
renal mineralization | 9 |
proximal humerus | 9 |
cell homeostasis | 9 |
cell help | 9 |
less severe | 9 |
consensus statements | 9 |
median number | 9 |
expressing cells | 9 |
felv fiv | 9 |
cd molecules | 9 |
group received | 9 |
linear mixed | 9 |
expression data | 9 |
elisa method | 9 |
controlled study | 9 |
may develop | 9 |
target cell | 9 |
without clinical | 9 |
crypt abscesses | 9 |
acquired immune | 9 |
prolapse syndrome | 9 |
one hand | 9 |
canine chronic | 9 |
inflammatory infiltrates | 9 |
enzyme activity | 9 |
storm syndrome | 9 |
shock protein | 9 |
patients present | 9 |
significantly inhibited | 9 |
charles spaniel | 9 |
freshly isolated | 9 |
body ingestion | 9 |
superoxide dismutase | 9 |
often seen | 9 |
one month | 9 |
current pandemic | 9 |
face visits | 9 |
mount sinai | 9 |
pfizer animal | 9 |
secondary gastrointestinal | 9 |
tcr signaling | 9 |
paediatric gastroenterology | 9 |
three cases | 9 |
services reported | 9 |
herpes simplex | 9 |
gastroenterol hepatol | 9 |
peg tube | 9 |
cell priming | 9 |
disease characterized | 9 |
end point | 9 |
molecular weight | 9 |
heavy chain | 9 |
neutropenic enterocolitis | 9 |
reactive oxygen | 9 |
streptococcus spp | 9 |
concentrations increased | 9 |
significantly elevated | 9 |
ra promoter | 9 |
veterinary students | 9 |
low levels | 9 |
colorectal adenomas | 9 |
surgical management | 9 |
carbon metabolism | 9 |
may show | 9 |
costimulatory molecules | 9 |
increased production | 9 |
time rt | 9 |
inflammatory reactions | 9 |
privately owned | 9 |
cases per | 9 |
proinflammatory cytokine | 9 |
gene sequencing | 9 |
dogs respectively | 9 |
diffuse large | 9 |
also tested | 9 |
eosinophilic bronchopneumopathy | 9 |
negatively correlated | 9 |
two weeks | 9 |
hours following | 9 |
cell level | 9 |
pediatric patients | 9 |
umbilical cord | 9 |
mitochondrial membrane | 9 |
resection specimens | 9 |
fusion proteins | 9 |
without significant | 9 |
lung function | 9 |
data available | 9 |
protein level | 9 |
renal azotemia | 9 |
samples using | 9 |
ibd treatments | 9 |
node status | 9 |
primary liver | 9 |
chronic mitral | 9 |
intracellular mucin | 9 |
signs may | 9 |
successful treatment | 9 |
acquired immunodeficiency | 9 |
relatively high | 9 |
renal damage | 9 |
baseline values | 9 |
neuroendocrine carcinoma | 9 |
feline pancreatitis | 9 |
tnf agents | 9 |
least hours | 9 |
fiv infection | 9 |
ibd inflammation | 9 |
arterial pressure | 9 |
ubiquitin ligase | 9 |
negative correlation | 9 |
draining lymph | 9 |
tlr agonists | 9 |
i ifn | 9 |
molecular mechanism | 9 |
signet ring | 9 |
dilutional parallelism | 9 |
regression model | 9 |
bloody diarrhea | 9 |
target genes | 9 |
also provided | 9 |
cells isolated | 9 |
red zone | 9 |
done using | 9 |
inflammatory infiltrate | 9 |
feline hyperthyroidism | 9 |
retrospectively evaluated | 9 |
diagnostic test | 9 |
induced activation | 9 |
initial presentation | 9 |
good agreement | 9 |
refractory pouchitis | 9 |
manual technique | 9 |
gastrointestinal lymphoma | 9 |
feline lymphoma | 9 |
disease groups | 9 |
bartonella species | 9 |
tcr signalling | 9 |
inflammatory processes | 9 |
last years | 9 |
domestic cats | 9 |
diastolic dysfunction | 9 |
intestinal neuronal | 9 |
four cats | 9 |
systolic dysfunction | 9 |
tyrosine phosphorylation | 9 |
identify potential | 9 |
right atrium | 9 |
physical examinations | 9 |
twentieth century | 9 |
care units | 9 |
reported incidence | 9 |
significant increases | 9 |
metabolic syndrome | 9 |
ultrasonographic findings | 9 |
siamese cats | 9 |
one sample | 9 |
gondii infection | 9 |
findings may | 9 |
study indicate | 9 |
treated animals | 9 |
release syndrome | 9 |
using anti | 9 |
malignant polyps | 9 |
dose aspirin | 9 |
immunohistochemical study | 9 |
reference genes | 9 |
peritoneal cavity | 9 |
septal defect | 9 |
randomly selected | 9 |
chimeric rhdv | 9 |
global burden | 9 |
statistically different | 9 |
hydrostatic pressure | 9 |
associated dysplasia | 9 |
er stress | 9 |
disease type | 8 |
major histocompatibility | 8 |
readily available | 8 |
oxide synthase | 8 |
new cases | 8 |
lpr lpr | 8 |
countries regions | 8 |
microbiota composition | 8 |
diastolic rv | 8 |
ng cm | 8 |
serum protein | 8 |
hek cells | 8 |
biliary tree | 8 |
study investigated | 8 |
membrane protein | 8 |
widely available | 8 |
anxiety level | 8 |
patient associations | 8 |
previous reports | 8 |
paneth cells | 8 |
disease characteristics | 8 |
time required | 8 |
ifa positive | 8 |
risk patients | 8 |
veterinary medical | 8 |
surface epithelial | 8 |
care delivery | 8 |
reduce inflammation | 8 |
may allow | 8 |
strongly suggest | 8 |
i interferon | 8 |
may explain | 8 |
severe infection | 8 |
care systems | 8 |
screening test | 8 |
inflamed joints | 8 |
cats tested | 8 |
veterinary clinics | 8 |
cell functions | 8 |
patients might | 8 |
inflammatory reaction | 8 |
may become | 8 |
metabolic pathways | 8 |
abdominal wall | 8 |
fluorescent protein | 8 |
conventional echocardiography | 8 |
cortisol concentrations | 8 |
pcr assays | 8 |
ventricular internal | 8 |
danlos syndrome | 8 |
nonlinear dynamical | 8 |
microarray studies | 8 |
portosystemic shunts | 8 |
enzyme immunoassay | 8 |
mirna expression | 8 |
serum amyloid | 8 |
highly variable | 8 |
studies reported | 8 |
clinical pathology | 8 |
american gastroenterological | 8 |
urine culture | 8 |
one year | 8 |
signaling molecules | 8 |
small molecule | 8 |
oral dose | 8 |
gi transit | 8 |
autophagy gene | 8 |
treated using | 8 |
cd null | 8 |
activated cells | 8 |
dai score | 8 |
glucose monitoring | 8 |
color doppler | 8 |
small dogs | 8 |
pressure measurements | 8 |
previously established | 8 |
sclerosing cholangitis | 8 |
infected animals | 8 |
seven patients | 8 |
consecutive measurements | 8 |
steroid therapy | 8 |
stimulatory molecules | 8 |
ehrlichia canis | 8 |
cell specific | 8 |
six cats | 8 |
gastric ulceration | 8 |
myenteric plexus | 8 |
urine antigen | 8 |
retrospective case | 8 |
secondary infection | 8 |
antitumor necrosis | 8 |
activated cd | 8 |
resection specimen | 8 |
also present | 8 |
infection compared | 8 |
tissue sections | 8 |
mortality rates | 8 |
diagnostic sensitivity | 8 |
marker cd | 8 |
previously published | 8 |
pump inhibitors | 8 |
precise diagnosis | 8 |
diagnostic testing | 8 |
kir dl | 8 |
consensus statement | 8 |
lymphocytic neoplasia | 8 |
culture medium | 8 |
mean serum | 8 |
i expression | 8 |
stromal cells | 8 |
immunomodulatory factors | 8 |
gas analysis | 8 |
brachycephalic dogs | 8 |
quantitative polymerase | 8 |
parvoviral enteritis | 8 |
interventricular septum | 8 |
canine pancreatitis | 8 |
test showed | 8 |
recently identified | 8 |
naturally acquired | 8 |
baos dogs | 8 |
kg sc | 8 |
healthy whwts | 8 |
electronic data | 8 |
high dose | 8 |
delta cortisol | 8 |
dogs presenting | 8 |
intestinal lymphoma | 8 |
biochemical parameters | 8 |
veterinary college | 8 |
hi cd | 8 |
common feline | 8 |
jak inhibitor | 8 |
culture system | 8 |
serious infections | 8 |
authors declare | 8 |
skull abnormalities | 8 |
detection limit | 8 |
hrct ga | 8 |
pericardial effusion | 8 |
cd antibodies | 8 |
data update | 8 |
tac levels | 8 |
blood mo | 8 |
eight healthy | 8 |
packed cell | 8 |
using three | 8 |
saudi arabia | 8 |
biological treatment | 8 |
proteomic analysis | 8 |
working group | 8 |
significantly affect | 8 |
examine whether | 8 |
gastroenterological association | 8 |
clinical experience | 8 |
examined using | 8 |
intestinal biopsies | 8 |
anal canal | 8 |
neonatal vg | 8 |
good clinical | 8 |
ibd center | 8 |
rbc gsh | 8 |
complete response | 8 |
feline panleukopenia | 8 |
specific igg | 8 |
high expression | 8 |
impedance measurements | 8 |
host response | 8 |
diagnostic criteria | 8 |
angiotensin i | 8 |
every days | 8 |
severe illness | 8 |
two major | 8 |
bacterial species | 8 |
high frequency | 8 |
spearman correlation | 8 |
database public | 8 |
cytokine milieu | 8 |
mice immunized | 8 |
spinal pain | 8 |
ckd cats | 8 |
chronic hepatitis | 8 |
ibd will | 8 |
multiorgan failure | 8 |
whitney test | 8 |
higher expression | 8 |
typically associated | 8 |
simplex virus | 8 |
significantly improved | 8 |
malignant colorectal | 8 |
national health | 8 |
ibd cohort | 8 |
feline diabetes | 8 |
ill dogs | 8 |
cat may | 8 |
recent data | 8 |
standard echocardiography | 8 |
squamous cell | 8 |
bile ducts | 8 |
bem score | 8 |
associated diarrhea | 8 |
traffi cking | 8 |
panleukopenia virus | 8 |
ms ms | 8 |
acid concentrations | 8 |
human gd | 8 |
cholangitis syndrome | 8 |
severe colitis | 8 |
antigen receptor | 8 |
interval ci | 8 |
colonic tissue | 8 |
blood sample | 8 |
inflammation may | 8 |
starting dose | 8 |
bacterial antigens | 8 |
echocardiographic variables | 8 |
lost weight | 8 |
poorly differentiated | 8 |
regurgitant jet | 8 |
golden retrievers | 8 |
prepatent period | 8 |
gastrointestinal stromal | 8 |
airway collapse | 8 |
th response | 8 |
median serum | 8 |
recently demonstrated | 8 |
complete remission | 8 |
binding protein | 8 |
high sensitivity | 8 |
veterinary literature | 8 |
eus fna | 8 |
activated human | 8 |
local immune | 8 |
extremely rare | 8 |
serum chemistry | 8 |
different serum | 8 |
dogs included | 8 |
adverse covid | 8 |
lymphoid follicles | 8 |
may present | 8 |
statistical differences | 8 |
negatively associated | 8 |
receptor antagonists | 8 |
urgent need | 8 |
discrete foreign | 8 |
cd dc | 8 |
cd cell | 8 |
hiv aids | 8 |
expressed genes | 8 |
also suggest | 8 |
spec fpl | 8 |
infection risk | 8 |
adjunctive therapy | 8 |
liver failure | 8 |
rna interference | 8 |
experimental exposure | 8 |
clinical utility | 8 |
first century | 8 |
presenting signs | 8 |
creatinine concentrations | 8 |
ae standard | 8 |
machine learning | 8 |
canine mscs | 8 |
speckle tracking | 8 |
glucose transport | 8 |
identifi cation | 8 |
grade lymphoma | 8 |
false positive | 8 |
cell apoptosis | 8 |
progressive interstitial | 8 |
veterinary clinic | 8 |
feline pancreas | 8 |
monte carlo | 8 |
outpatient clinics | 8 |
ple dogs | 8 |
study reported | 8 |
therapeutic effects | 8 |
acute necrotizing | 8 |
th percentile | 8 |
common finding | 8 |
additional information | 8 |
based studies | 8 |
ctni concentrations | 8 |
endoscopy unit | 8 |
affected individuals | 8 |
stricture formation | 8 |
outflow obstruction | 8 |